These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15714348)

  • 1. Costs of treatment of colorectal cancer in different settings in Germany.
    Hieke K; Kleeberg UR; Stauch M; Grothey A
    Eur J Health Econ; 2004 Oct; 5(3):270-3. PubMed ID: 15714348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Grothey A; Kleeberg UR; Stauch M; Hieke K
    Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
    Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
    Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
    Hochster HS
    Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Cassidy J; Schmoll HJ; Van Cutsem E
    J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
    Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
    Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
    Best JH; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
    Lopatriello S; Amoroso D; Donati S; Alabiso O; Forti L; Fornasiero A; Smergo A; Lalli A; Iacono C; Lucenti A; D'Alonzo L; Negrini C
    Eur J Cancer; 2008 Nov; 44(17):2615-22. PubMed ID: 18805000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
    Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
    Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
    De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
    J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
    Douillard JY; Tilleul P; Ychou M; Dufour P; Perrocheau G; Seitz JF; Maes P; Lafuma A; Husseini F
    Oncology; 2007; 72(3-4):248-54. PubMed ID: 18185019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of capecitabine use as first line treatment in patients with advanced gastric carcinoma in Portugal].
    Macedo A; Pereira C; Gonçalves J; Sousa C
    Acta Med Port; 2009; 22(6):827-32. PubMed ID: 20350467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
    Chu E; Cartwright TH
    J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
    Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.